Today: 7 February 2026
Subscribe
Browse Category

LSE:GSK News 15 January 2026 - 28 January 2026

GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK shares dropped 1.8% to 1,828.5 pence by mid-morning Wednesday in London, reversing gains from earlier in the week. The decline followed news that the European Commission expanded approval of GSK’s RSV vaccine Arexvy to all adults 18 and older. Pfizer also secured similar approval for its RSV shot. Investors await guidance from European health agencies and GSK’s earnings report on February 4.
28 January 2026
····
GSK share price: China’s Trelegy asthma nod puts the stock in focus for Monday — what to watch next

GSK share price: China’s Trelegy asthma nod puts the stock in focus for Monday — what to watch next

China approved a new asthma use for GSK’s Trelegy Ellipta inhaler. GSK shares closed down 3.5p at 1,801p in London on Friday. The company said Trelegy is now the first single-inhaler triple therapy cleared in China for both asthma and COPD. Investors await GSK’s Feb. 4 results for signals on China demand.
25 January 2026
······
GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK shares closed down 0.2% at 1,801 pence in London Friday after China approved Trelegy Ellipta for uncontrolled asthma in adults. The expanded label gives GSK access to an estimated 46 million adults with asthma in China. Investors await GSK’s Q4 and full-year results, set for Feb. 4. The FTSE 100 slipped 0.07% on the day.
24 January 2026
······
GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk

GSK shares rose 0.1% in early London trading as investors assessed the $2.2 billion acquisition of RAPT Therapeutics and changes to ViiV Healthcare’s ownership. The deal brings ozureprubart, a mid-stage food-allergy drug, into GSK’s pipeline. Pfizer will exit ViiV, with Shionogi raising its stake to 21.7%. Uncertainty over U.S. vaccine policy clouds the outlook ahead of GSK’s Feb. 4 results.
22 January 2026
····
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Rapt Therapeutics shares surged 64% to $57.57 in after-hours trading after GSK agreed to acquire the company for $58 a share in cash, valuing Rapt at about $2.2 billion. The deal centers on ozureprubart, a long-acting anti-IgE antibody. GSK plans to launch a tender offer within 10 business days. Closing depends on a majority of Rapt shares being tendered and U.S. antitrust clearance.
21 January 2026
·····
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug

RAPT Therapeutics shares soared 64% to $57.54 after GSK announced a $58-per-share cash acquisition, valuing the biotech at $2.2 billion. The deal centers on ozureprubart, an experimental anti-IgE drug for food allergies. GSK plans to launch a tender offer within 10 business days, pending antitrust review. RAPT’s stock hovered just below the offer price as investors watched for regulatory developments.
20 January 2026
·····
GSK share price slips into the weekend as investors brace for Feb. 4 results

GSK share price slips into the weekend as investors brace for Feb. 4 results

London, Jan 18, 2026, 07:58 GMT — Market closed. GSK shares dipped 1.7% on Friday, ending at 1,816.5 pence. That’s underperforming the flat FTSE 100, with trading volume ticking above recent levels. (MarketWatch) London markets are closed Sunday, leaving investors to focus beyond a slow news day and on the next major event: GSK’s Q4 earnings, set for Feb. 4. (GSK) The next dividend timetable is set to kick off on the same day. GSK’s calendar lists the ex-dividend date for the quarter as Feb. 19, with the payout scheduled for April 9. (GSK) A regulatory filing late Friday revealed
18 January 2026
····
GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

London, January 17, 2026, 07:58 GMT — The market has closed. Shares of GSK plc slipped 1.7% to 1,817 pence on Friday, lagging behind a flat FTSE 100 as volume spiked late in the session. The stock closed 11.7% below its 52-week peak of 2,058 pence reached on Dec. 19. Trading volume hit 12.6 million shares, well above the 50-day average of 8.2 million. (MarketWatch) This matters because the selling is hitting before the drugmaker’s full-year results drop in early February, a time when the market often penalizes even minor disappointments. The surge in volume indicates some investors are making
17 January 2026
·····
GSK stock rises as pipeline talk hits JPM conference, with Feb. 4 earnings in focus

GSK stock rises as pipeline talk hits JPM conference, with Feb. 4 earnings in focus

New York, January 15, 2026, 02:30 EST — The market has closed. GSK plc’s shares traded in the U.S. climbed 1.8% on Wednesday, closing at $50.79. The stock remains in the spotlight heading into Thursday’s session. U.S. markets were closed overnight, leaving investors to watch for follow-through in premarket trading and in London after a week packed with conference headlines and positioning. The scene is set: investors are eager for clues on how major drugmakers intend to protect sales amid growing competition and aging products. For GSK, the coming weeks will focus on whether management can highlight new launches and
15 January 2026
······
1 2 3 4 5

Stock Market Today

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

CapitaLand Investment share price jumps as CapitaLand REIT payouts roll in — what’s next for 9CI

7 February 2026
CapitaLand Investment shares rose 1.3% to S$3.12 on Friday, bucking a 0.8% drop in Singapore’s benchmark index. CapitaLand Integrated Commercial Trust reported a 16.4% jump in second-half distributable income, while CapitaLand Ascendas REIT posted a 1.4% full-year rise. CapitaLand China Trust saw full-year DPU fall to 4.82 cents amid weaker yuan and occupancy. CLI reports FY2025 results on Feb. 11.
Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

Keppel stock holds near 12-year high after profit jump, special dividend; buyback adds support

7 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, after surging 6.1% the previous day on stronger FY2025 profit and a larger dividend plan. The company bought back 151,400 shares for about S$1.74 million. Keppel reported a 29% rise in full-year profit to S$1.02 billion and proposed a total distribution of 47 cents per share, including a special dividend partly paid in Keppel REIT units.
Go toTop